ChromaDex (CDXC) 10-Q 6 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 27, 2014	Nov. 05, 2014
Document And Entity Information	'	'
Entity Registrant Name	'ChromaDex Corp.	'
Entity Central Index Key	'0001386570	'
Document Type	'10-Q	'
Document Period End Date	27-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--01-03	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	106,924,193
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 27, 2014	Dec. 28, 2013
Current Assets	'	'
Cash	$1,203,758	$2,261,336
Trade receivables, less allowance for doubtful accounts and returns September 27, 2014 $33,000; December 28, 2013 $9,000	2,528,638	838,793
Other receivable	'	215,000
Inventories	2,286,086	2,204,125
Prepaid expenses and other assets	294,296	271,445
Total current assets	6,312,778	5,790,699
Leasehold Improvements and Equipment, net	1,293,702	1,063,239
Other Noncurrent Assets	'	'
Deposits	52,046	43,460
Long-term investment in affiliate	773,801	1,887,844
Intangible assets, net	266,824	201,650
Total other noncurrent assets	1,092,671	2,132,954
Total assets	8,699,151	8,986,892
Current Liabilities	'	'
Accounts payable	2,270,645	1,440,910
Accrued expenses	857,854	656,707
Current maturities of capital lease obligations	162,566	138,887
Customer deposits and other	225,917	546,044
Deferred rent, current	65,040	55,586
Total current liabilities	3,582,022	2,838,134
Capital lease obligations, less current maturities	456,969	280,342
Deferred rent, less current	156,779	202,965
Total Liabilities	4,195,770	3,321,441
Stockholders' Equity	'	'
Common stock, $.001 par value; authorized 150,000,000 shares; issued and outstanding September 27, 2014 105,239,985 and December 28, 2013 104,524,738 shares	105,240	104,525
Additional paid-in capital	42,695,089	39,697,063
Accumulated deficit	-38,296,948	-34,136,137
Total stockholders' equity	4,503,381	5,665,451
Total liabilities and stockholders' equity	$8,699,151	$8,986,892

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 27, 2014	Dec. 28, 2013
Statement of Financial Position [Abstract]	'	'
Trade receivables, less allowance for doubtful accounts and returns	$33,000	$9,000
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	105,239,985	104,524,738
Common Stock, Shares, Outstanding	105,239,985	104,524,738

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Income Statement [Abstract]	'	'	'	'
Sales, net	$4,139,710	$2,718,207	$11,070,002	$7,759,668
Cost of sales	2,616,764	1,968,020	7,163,282	5,375,903
Gross profit	1,522,946	750,187	3,906,720	2,383,765
Operating expenses:	'	'	'	'
Sales and marketing	518,662	505,068	1,554,777	1,866,051
General and administrative	1,651,718	1,453,611	6,458,027	4,155,792
Loss from investment in affiliate	'	33,281	21,543	33,281
Operating expenses	2,170,380	1,991,960	8,034,347	6,055,124
Operating loss	-647,434	-1,241,773	-4,127,627	-3,671,359
Nonoperating income (expense):	'	'	'	'
Interest income	230	179	1,175	679
Interest expense	-12,449	-8,669	-34,359	-24,521
Nonoperating expenses	-12,219	-8,490	-33,184	-23,842
Net loss	($659,653)	($1,250,263)	($4,160,811)	($3,695,201)
Basic and Diluted loss per common share	($0.01)	($0.01)	($0.04)	($0.04)
Basic and Diluted weighted average common shares outstanding	106,610,400	101,309,939	106,290,782	98,590,008

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 28, 2013	$104,525	$39,697,063	($34,136,137)	$5,665,451
Beginning Balance, Shares at Dec. 28, 2013	104,524,738	'	'	'
Exercise of stock options, Shares	34,363	'	'	'
Exercise of stock options, Amount	34	27,066	'	27,100
Issuance of unvested restricted stock, Shares	1,090,000	'	'	'
Issuance of unvested restricted stock, Amount	1,090	'	'	1,090
Unvested restricted stock, Shares	-1,090,000	'	'	'
Unvested restricted stock, Amount	-1,090	'	'	-1,090
Share-based compensation, Shares	'	'	'	'
Share-based compensation, Amount	'	949,943	'	949,943
Net loss	'	'	-1,848,016	-1,848,016
Ending Balance, Amount at Mar. 29, 2014	104,559	40,674,072	-35,984,153	4,794,478
Ending Balance, Shares at Mar. 29, 2014	104,559,101	'	'	'
Exercise of stock options, Shares	24,136	'	'	'
Exercise of stock options, Amount	24	17,971	'	17,995
Issuance of unvested restricted stock, Shares	96,000	'	'	'
Issuance of unvested restricted stock, Amount	96	'	'	96
Unvested restricted stock, Shares	-96,000	'	'	'
Unvested restricted stock, Amount	-96	'	'	-96
Share-based compensation, Shares	6,000	'	'	'
Share-based compensation, Amount	6	1,030,689	'	1,030,695
Stock issued to settle outstanding payable balance, Shares	126,605	'	'	'
Stock issued to settle outstanding payable balance, Amount	127	128,367	'	128,494
Net loss	'	'	-1,653,142	-1,653,142
Ending Balance, Amount at Jun. 28, 2014	104,716	41,851,099	-37,637,295	4,318,520
Ending Balance, Shares at Jun. 28, 2014	104,715,842	'	'	'
Exercise of stock options, Shares	453,143	'	'	'
Exercise of stock options, Amount	453	403,610	'	404,063
Issuance of unvested restricted stock, Shares	'	'	'	'
Issuance of unvested restricted stock, Amount	'	'	'	'
Unvested restricted stock, Shares	'	'	'	'
Unvested restricted stock, Amount	'	'	'	'
Share-based compensation, Shares	71,000	'	'	'
Share-based compensation, Amount	71	431,380	'	431,451
Stock issued to settle outstanding payable balance, Shares	'	'	'	'
Stock issued to settle outstanding payable balance, Amount	'	9,000	'	9,000
Net loss	'	'	-659,653	-659,653
Ending Balance, Amount at Sep. 27, 2014	$105,240	$42,695,089	($38,296,948)	$4,503,381
Ending Balance, Shares at Sep. 27, 2014	105,239,985	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 27, 2014	Sep. 28, 2013
Cash Flows From Operating Activities	'	'
Net loss	($4,160,811)	($3,695,201)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of leasehold improvements and equipment	161,712	187,667
Amortization of intangibles	24,826	16,819
Share-based compensation expense	2,467,720	1,059,653
Gain on exchange of equipment	-17,301	'
Loss from disposal of equipment	'	68,378
Loss from investment in affiliate	-21,543	-33,281
Changes in operating assets and liabilities:	'	'
Trade receivables	-1,689,845	931,904
Other receivable	215,000	'
Inventories	-81,961	-479,924
Prepaid expenses and other assets	-87,068	-50,991
Accounts payable	967,229	-712,138
Accrued expenses	201,147	72,336
Customer deposits and other	-320,127	349,378
Deferred rent	-36,732	45,661
Net cash used in operating activities	-2,334,668	-2,173,177
Cash Flows From Investing Activities	'	'
Purchases of leasehold improvements and equipment	-53,428	-117,523
Purchases of intangible assets	-90,000	-69,000
Proceeds from sale of assets	'	1,000,000
Proceeds from sale of equipment	1,356	'
Proceeds from investment in affiliate	1,092,500	225,000
Net cash provided by investing activities	950,428	1,038,477
Cash Flows From Financing Activities	'	'
Proceeds from exercise of stock options	449,158	138,369
Proceeds from exercise of warrants	'	1,638,748
Principal payments on capital leases	-122,496	-74,993
Net cash provided by financing activities	326,662	1,702,124
Net (decrease) increase in cash	-1,057,578	567,424
Cash Beginning of Period	2,261,336	520,000
Cash Ending of Period	1,203,758	1,087,424
Supplemental Disclosures of Cash Flow Information	'	'
Cash payments for interest	34,359	24,521
Supplemental Schedule of Noncash Investing Activity	'	'
Capital lease obligation incurred for the purchase of equipment	322,802	171,851
Retirement of fully depreciated equipment - cost	56,110	'
Retirement of fully depreciated equipment - accumulated depreciation	-56,110	'
Supplemental Schedule of Noncash Operating Activity	'	'
Stock issued to settle outstanding payable balance	137,494	'
Supplemental Schedule of Noncash Share-based Compensation	'	'
Stock awards issued for services rendered in prior period	'	14,560
Changes in prepaid expenses associated with share-based compensation	55,631	119,375
Supplemental Schedule of Noncash Activities Related to Sale of BlueScience Consumer Product Line	'	'
Assets transferred	'	3,526,677
Liabilities transferred	'	368,873
Carrying value of long-term investment in affiliate, net of $1,000,000 cash proceeds	'	$2,157,804

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Parenthetical) (USD $)	9 Months Ended
	Sep. 27, 2014
Statement of Cash Flows [Abstract]	'
Cash proceeds	$1,000,000

Interim_Financial_Statements

Interim Financial Statements	9 Months Ended
	Sep. 27, 2014
Interim Financial Statements	'
Note 1. Interim Financial Statements	'
	The accompanying financial statements of ChromaDex Corporation (the “Company”) and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of September 27, 2014 and results of operations and cash flows for the three and nine months ended September 27, 2014 and September 28, 2013. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 28, 2013 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 27, 2014. Operating results for the nine months ended September 27, 2014 are not necessarily indicative of the results to be achieved for the full year ending on January 3, 2015.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
	The balance sheet at December 28, 2013 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

Nature_of_Business_and_Liquidi

Nature of Business and Liquidity	9 Months Ended
	Sep. 27, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Note 2. Nature of Business and Liquidity	'
	Nature of business:  The Company is a natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its business model that utilizes its wholly owned business units, including ingredient technologies, natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting).  The Company provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries.  The Company acquired Spherix Consulting, Inc. on December 3, 2012, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
	Liquidity:  The Company has incurred a loss from operations of approximately $4,128,000 and a net loss of approximately $4,161,000 for the nine-month period ended September 27, 2014.  As of September 27, 2014, cash totaled approximately $1,204,000.  Subsequent to the nine-month period ended September 27, 2014, the Company entered into a loan and security agreement with Hercules Technology II, L.P., as lender (“Lender”) and Hercules Technology Growth Capital Inc., as agent.  Lender will provide the Company with access to a term loan up to $5 million.  The first $2.5 million of the term loan was funded at closing, and is repayable in installments over 30 months, following an initial interest-only period of twelve months after closing.  The remaining $2.5 million of the term loan can be drawn down at the Company’s option at any time but no later than July 31, 2015.  For more details on the term loan, please see Note 11. Subsequent Events of the Financial Statements.
	With the term loan described above, management believes it will be able to support operations of the Company with its current cash and cash from operations through at least November 6, 2015; however there can be no assurance that unforeseen circumstances will not require the Company to seek additional financing.  If the Company determines that it shall require additional financing to further enable it to achieve its long-term strategic objectives, there can be no assurance that such financing will be available on terms favorable to it or at all.  If adequate financing is not available, the Company may delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative expenses.  The inability to raise additional financing may have a material adverse effect on the future performance of the Company.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 27, 2014
Accounting Policies [Abstract]	'
Note 3. Significant Accounting Policies	'
	Basis of presentation:  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company's fiscal year ends on the Saturday closest to December 31, and the Company’s normal fiscal quarters end on the Saturday 13 weeks after the last fiscal year end or fiscal quarter end.  Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date.  The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks, and will end on January 3, 2015.
	Changes in accounting estimate: During the nine-month period ended September 27, 2014, the Company evaluated assumptions for estimating the fair value of the Company’s stock options.  The Company uses the Black-Scholes based option valuation model, which requires assumptions on (i) volatility, (ii) expected dividends, (iii) expected term and (iv) risk-free rate.  While evaluating the assumptions on volatility, the Company determined that the historical volatility the Company’s common stock needs to be considered when estimating the expected volatility.  Previously, the Company calculated expected volatility based on publicly held companies in similar industries and did not consider the historical volatility of the Company’s common stock, as the historical measurement period that was available to compute the volatility rate of the Company’s common stock was shorter than the expected life of the options.
	For the stock options granted during the nine-month period ended September 27, 2014, the Company calculated expected volatility rate based on the combined volatility of publicly held companies in similar industries and volatility of the Company’s common stock.  A 20~30% weight was assigned to the volatility of the Company’s common stock as the historical volatility of the Company’s common stock covers only the period since June 2008 in a thinly traded market.  The weighted average expected volatility for the stock options granted during the nine-month period ended September 27, 2014 following the update to our estimate is approximately 73%.  The weighted average expected volatility would have been approximately 30%, had we computed solely based on the volatility rates of similarly situated public companies. For the year ended December 28, 2013, the weighted average expected volatility the Company used to estimate the fair value of the Company’s stock options granted was approximately 33%.
	Inventories:  Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  The amounts of major classes of inventory as of September 27, 2014 and December 28, 2013 are as follows:
		27-Sep-14		28-Dec-13
	Reference standards	$	1,715,507	$	1,769,160
	Bulk ingredients		866,509		694,965
			2,582,016		2,464,125
	Less valuation allowance		295,930		260,000
		$	2,286,086	$	2,204,125
	Recent accounting standards: In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements.
	In August 2014, the FASB issued ASU 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.”  Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this ASU provide that guidance.  In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures.  The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued).  The amendments in this ASU are effective for public and nonpublic entities for annual periods ending after December 15, 2016. Early adoption is permitted. On September 27, 2014, the Company early adopted ASU 2014-15.  The adoption of ASU 2014-15 had no impacts on the Company’s consolidated financial statements.

Loss_Per_Share_Applicable_to_C

Loss Per Share Applicable to Common Stockholders	9 Months Ended
	Sep. 27, 2014
Loss Per Share Applicable To Common Stockholders	'
Note 4. Loss Per Share Applicable to Common Stockholders	'
	The following table sets forth the computations of loss per share amounts applicable to common stockholders for the three and nine months ended September 27, 2014 and September 28, 2013:
		Three Months Ended						Nine Months Ended
		27-Sep-14			28-Sep-13			27-Sep-14			28-Sep-13
	Net loss	$	(659,653	)	$	(1,250,263	)	$	(4,160,811	)	$	(3,695,201	)
	Basic and diluted loss per common share	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.04	)
	Weighted average common shares outstanding (1):		106,610,400			101,309,939			106,290,782			98,590,008
	Potentially dilutive securities (2):
	Stock options		13,890,766			13,609,700			13,890,766			13,609,700
	Warrants		-			535,000			-			535,000
	(1) Includes 1,676,175 and 500,000 weighted average nonvested shares of restricted stock for the three months ended September 27, 2014 and September 28, 2013, respectively, and 1,606,380 and 500,000 weighted average nonvested shares of restricted stock for the nine months ended September 27, 2014 and September 28, 2013, respectively, which are participating securities that feature voting and dividend rights.
	(2) Excluded from the computation of loss per share as their impact is antidilutive.

Investment_in_Affiliate

Investment in Affiliate	9 Months Ended
	Sep. 27, 2014
Investment In Affiliate	'
Note 5. Investment in Affiliate	'
	During the year ended December 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci International Inc. (“NeutriSci”) and consummated the sale of BluScience consumer product line to NeutriSci.  The Company is using the cost recovery method to account the sale transaction, which was estimated at approximately $3,157,804.  The consideration received consisted of following: (a) a $1,000,000 cash payment; (b) a $2,500,000 senior convertible secured note (convertible into 625,000 shares Series I Preferred Stock); and (c) 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class “A” common shares of NeutriSci, representing an aggregate of 19% of the NeutriSci shares at the date of the transaction.
	The Company has previously applied the equity method of accounting due to a significant influence that it had obtained from the financial instruments noted above, and the carrying value, which includes the Senior Note, was reflected as long-term investment in affiliate in the Company’s consolidated balance sheet at the date of transaction.  The initial carrying value of this investment recognized at the date of transaction was $2,157,804, which is the Company’s unrecovered cost or the difference between the net assets transferred to NeutriSci and the initial monetary consideration received.  The 669,708 shares of Series I Preferred Shares and the senior convertible secured note were accounted for as one long-term investment in NeutriSci.  Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets transferred has been recovered.
	Sale of Senior Secured Convertible Note
	On December 30, 2013, the Company assigned the Senior Note to an unrelated third party for $1,250,000.  $2,275,000 remained outstanding on the Senior Note at the date of the assignment.  The Company also paid legal fees of $7,500 out of the proceeds of the purchase price.  The Company also agreed to transfer to the third party a number of shares of preferred stock of NeutriSci having a value of $500,000 upon the earlier of (a) December 31, 2014; or (b) the consummation by NeutriSci of any action resulting in the shares of its common stock being listed on an exchange.  There is no recourse provision to the Company associated with the assignment of the note.  In connection with the assignment of the note, the Company paid Palladium Capital Advisors, LLC (“Palladium”), a placement agent, a cash fee of $150,000 and agreed to transfer to Palladium a number of shares of preferred stock of NeutriSci having a value of $50,000 upon the consummation by NeutriSci of any action resulting in the shares of its common stock being listed on an exchange.  The net proceeds received from the assignment of the Senior Note have been charged against the carrying value of the long-term investment in affiliate.
	Subsequent to the consummation of the sale of BluScience consumer product line, NeutriSci has issued additional 950 shares of Series I Preferred Shares pursuant to anti-dilution provision.  There was no accounting transaction for this additional shares received as the Company is using the cost recovery method to account the BluScience sale transaction.  As of September 27, 2014, the Company holds a total of 670,658 shares of Series I Preferred Shares.
	As of September 27, 2014, the Company has not transferred preferred stock of NeutriSci to either the unrelated party or Palladium.  Based on the latest estimates of share price of Neutrisci upon listing, the Company would transfer approximately 110,000 shares of Series I Preferred Shares to the unrelated party and approximately 11,000 shares of Series I Preferred Shares, contingent upon NeutriSci’s common stock being listed on an exchange.  If NeutriSci’s common stock does not list on an exchange by December 31, 2014, then the Company would transfer approximately 250,000 shares of Series I Preferred Shares and approximately 25,000 shares of Series I Preferred Shares based on the terms of the assignment of the note.
	Loss of Significant Influence
	As a result of the assignment of the Senior Note described above, the Company no longer has a significant influence on NeutriSci as of December 30, 2013.  As a result, the Company has discontinued applying equity method of accounting and has applied cost method of accounting from December 30, 2013.  The adjusted carrying amount as of December 30, 2013 became the new cost figure for the investment and no retrospective adjustments to the financial statements have been made.
	The Company had elected to record equity method adjustments in losses on the investment in NeutriSci, with a three-month lag, as the financial information of NeutriSci was not available in a timely manner.  The equity method adjustment for the previously unaccounted NeutriSci’s operations from October 1, 2013 to December 31, 2013 is recorded during the nine-month period ended September 27, 2014, and is incorporated into the adjusted carrying amount of the investment.
	Sales, gross profit, net loss of NeutriSci for the three months ended December 31, 2013 and the changes in carrying value and the Company ownership percentage through December 30, 2013 are summarized as follows:
		December 31,
		2013
	Sales	$	60,575
	Gross profit		33,619
	Net loss	$	(435,208	)
	Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation
		Carrying			Ownership
		Value			Percentage
	At December 28, 2013	$	1,887,844			4.9	%
	Company's share of NeutriSci's loss for the three-month period ended December 31, 2013; previously not recognized due to a three-month lag		(21,543	)		-
	Proceeds from assignment of the Senior Note		(1,092,500	)		-
	At December 30, 2013	$	773,801			4.9	%
	Valuation assessment of Investment
	As of September 27, 2014, the Company has determined that there is no other-than-temporary impairment of the carrying amounts of its investment in NeutriSci.  The Company will continue to monitor NeutriSci’s performance and evaluate if there are any such events or indicators to consider.

Leasehold_Improvements_and_Equ

Leasehold Improvements and Equipment	9 Months Ended
	Sep. 27, 2014
Leasehold Improvements And Equipment	'
Note 6. Leasehold Improvements and Equipment	'
	Leasehold improvements and equipment consisted of the following:
		27-Sep-14		28-Dec-13
	Laboratory equipment	$	3,028,644	$	2,782,364
	Leasehold improvements		495,240		491,125
	Computer equipment		329,737		372,851
	Furniture and fixtures		13,039		18,313
	Office equipment		7,877		7,877
	Construction in progress		159,277		40,126
			4,033,814		3,712,656
	Less accumulated depreciation		2,740,112		2,649,417
		$	1,293,702	$	1,063,239
	Depreciation expense on leasehold improvements and equipment included in the consolidated statement of operations for the nine months ended September 27, 2014 and September 28, 2013 was approximately $162,000 and $188,000, respectively.
	During the nine months ended September 27, 2014, the Company disposed of approximately $56,000 of fully depreciated equipment.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 27, 2014
Share-Based Compensation	'
Note 7. Share-Based Compensation	'
	7A. Employee Share-Based Compensation
	Stock Option Plans
	The fair value of the Company’s stock options was estimated at the date of grant using the Black-Scholes option pricing model.  The table below outlines the weighted average assumptions for options granted to employees during the nine months ended September 27, 2014.
	Nine Months Ended September 27, 2014
	Expected volatility		73.55	%
	Expected dividends		0	%
	Expected term	5.7 years
	Risk-free rate		1.86	%
	The weighted average grant date fair value of options granted during the nine months ended September 27, 2014 was $0.91.
	Service Period Based Stock Options
	The majority of options granted by the Company feature service conditions.  Accordingly, these options vest ratably over specified periods of approximately 3 to 5 years following the date of grant.
	The following table summarizes our stock option activity during the nine months ended September 27, 2014:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 28, 2013		12,113,655		$	1.06		7.43
	Options Granted		2,033,987			1.37		10
	Options Classification from Employee to Non-Employee		(113,151	)		0.76
	Options Exercised		(511,642	)		0.88
	Options Expired		(253,900	)		1
	Options Forfeited		(628,634	)		1.11
	Outstanding at September 27, 2014		12,640,315		$	1.12		7.22	$	1,475,920
	Exercisable at September 27, 2014		8,822,108		$	1.13		6.53	$	1,071,805
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $1.06 on the last day of business for the period ended September 27, 2014.
	As of September 27, 2014, there was approximately $2,035,000 of total unrecognized compensation expense expected to be recognized over a weighted average period of 2.12 years.
	Restricted Stock
	Restricted stock awards granted by the Company to employees have vesting conditions that are unique to each award.
	The following table summarizes activity of restricted stock awards granted to employees at September 27, 2014 and changes during the nine months then ended:
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 28, 2013		500,000		$	0.69
	Granted		1,090,000			1.41
	Vested		-			-
	Forfeited		-			-
	Unvested shares at September 27, 2014		1,590,000		$	1.18
	Expected to Vest as of September 27, 2014		1,590,000		$	1.18
	On January 2, 2014, the Company awarded an aggregate of 1,090,000 shares of restricted stock to the Company’s officers and members of the board of directors.  These shares shall vest upon the earlier to occur of the following: (i) the market price of the Company’s stock exceeds a certain price, or (ii) one of other certain triggering events, including the termination of the officers and members of the board of directors without cause for any reason.  The fair values of these restricted stock awards were based on the trading price of the Company’s common stock on the date of grant.  The expense related to the restricted stock award has been amortized over the period of six months through July 1, 2014, as the Company determined the requisite service period to be 6 months as that is when they are eligible to vest.
	Employee Option and Restricted Stock Compensation
	The Company recognized compensation expense of approximately $388,000 and $2,359,000 in general and administrative expenses in the statement of operations for the three and nine months ended September 27, 2014, respectively, and $244,000 and $817,000 for the three and nine months ended September 28, 2013, respectively.
	7B. Non-Employee Share-Based Compensation
	Stock Option Plans
	The following table summarizes activity of stock options granted to non-employees at September 27, 2014 and changes during the nine months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 28, 2013		847,300		$	1.44		5.74
	Options Granted		90,000			1.24		10
	Options Classification from Employee to Non-Employee		113,151			0.76
	Options Exercised		-			-
	Options Forfeited		-			-
	Outstanding at September 27, 2014		1,050,451		$	1.35		5.73	$	64,067
	Exercisable at September 27, 2014		960,451		$	1.36		5.34	$	64,067
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $1.06 on the last day of business for the period ended September 27, 2014.
	Stock Awards
	On July 1, 2014, the Company awarded 65,000 shares of the Company’s common stock that were fully vested and non-forfeitable to a non-employee.  The fair value of the award, which amounted to $83,850 was based on the trading price of the Company’s stock on the date of grant.  The expense related to this stock award is being amortized over the period of approximately 7 months, as the services relating to this award are being provided over this period of time.  The expense the Company recognized for this award was approximately $35,000 for the nine months ended September 27, 2014.  During the nine months ended September 28, 2013, the Company awarded an aggregate of 600,000 shares of the Company’s common stock to non-employees and recognized approximately $238,000 for the expense.
	As of September 27, 2014, there was approximately $49,000 of total unrecognized compensation expense related to the stock award to a non-employee.  That cost is expected to be recognized over a period of approximately 4 months as of September 27, 2014.
	Restricted Stock
	Restricted stock awards granted by the Company to non-employees generally feature time vesting service conditions, specified in the respective service agreements.  Restricted stock awards issued to non-employees are accounted for at current fair value through the vesting period.  The fair value of vested non-employee restricted shares awarded during the nine months ended September 27, 2014 was approximately $15,000, which represents the market value of the Company’s common stock on respective vesting dates charged to expense.
	The following table summarizes activity of restricted stock awards issued to non-employees at September 27, 2014 and changes during the nine months then ended:
					Weighted Average
	Shares			Fair Value
Unvested shares at December 28, 2013		-		$	-
Granted		96,000			1.3
Vested		(12,000	)		1.28
Forfeited		-			-
Unvested shares expected to vest at September 27, 2014		84,000		$	1.06
As of September 27, 2014, there was approximately $87,000 of total unrecognized compensation expense related to the restricted stock award to a non-employee.  That cost is expected to be recognized over a period of 3.4 years as of September 27, 2014.
Non-Employee Option, Stock and Restricted Stock Compensation
The Company recognized share-based compensation expense of approximately $43,000 and $109,000 in general and administrative expenses in the statement of operations for the three and nine months ended September 27, 2014, respectively, and $87,000 and $243,000 for the three and nine months ended September 28, 2013, respectively.

Stock_Issuance

Stock Issuance	9 Months Ended
	Sep. 27, 2014
Stock Issuance	'
Note 8. Stock Issuance	'
	On June 11, 2014, the Company issued 44,605 shares of common stock to a vendor to settle an outstanding payable balance of $52,188.
	On June 18, 2014, the Company issued 82,000 shares of common stock to a vendor to settle an outstanding payable balance of $76,306 and payment of 6 months of $3,000 per month monthly retainer fees from July 2014 through December 2014.

Business_Segments

Business Segments	9 Months Ended
	Sep. 27, 2014
Business Segments	'
Note 9. Business Segmentation	'
	Since the year ended December 28, 2013, the Company has generated significant revenue from its ingredients operations and has made operational changes, including changes in the organizational structure to support the ingredients operations.  As a result, on December 29, 2013, the Company began segregating its financial results for ingredients operations, and has following three reportable segments.
		●	Core standards, and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, reference materials, and related contract services.
		●	Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries including the nutritional supplement, food and beverage and animal health industries.
		●	Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
	The “Other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination.  The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.
			Core Standards					Scientific and
			and Contract					Regulatory
	Three months ended September 27, 2014		Services			Ingredients		Consulting segment		Other			Total
			segment			segment
	Net sales		$	1,814,622		$	2,031,250	$	293,838	$	-		$	4,139,710
	Cost of sales			1,239,356			1,200,790		176,618		-			2,616,764
	Gross profit			575,266			830,460		117,220		-			1,522,946
	Operating expenses:
	Sales and marketing			259,951			243,068		15,643		-			518,662
	General and administrative			-			-		-		1,651,718			1,651,718
	Operating expenses			259,951			243,068		15,643		1,651,718			2,170,380
	Operating income (loss)		$	315,315		$	587,392	$	101,577	$	(1,651,718	)	$	(647,434	)
			Core Standards					Scientific and
			and Contract					Regulatory
	Three months ended September 28, 2013		Services			Ingredients		Consulting segment		Other			Total
			segment			segment
	Net sales		$	1,574,970		$	780,489	$	362,749	$	-		$	2,718,207
	Cost of sales			1,309,562			484,511		173,947		-			1,968,020
	Gross profit			265,408			295,977		188,802		-			750,187
	Operating expenses:
	Sales and marketing			328,043			165,025		12,000		-			505,068
	General and administrative			-			-		-		1,453,611			1,453,611
	Loss from investment in affiliate			-			-		-		33,281			33,281
	Operating expenses			328,043			165,025		12,000		1,486,892			1,991,960
	Operating income (loss)		$	(62,635	)	$	130,952	$	176,802	$	(1,486,892	)	$	(1,241,773	)
			Core Standards
			and Contract					Regulatory
	Nine months ended September 27, 2014		Services segment			Ingredients		Consulting segment		Other			Total
						segment
	Net sales		$	5,407,455		$	4,889,431	$	773,116	$	-		$	11,070,002
	Cost of sales			3,728,521			2,962,505		472,256		-			7,163,282
	Gross profit			1,678,934			1,926,926		300,860		-			3,906,720
	Operating expenses:
	Sales and marketing			694,523			793,414		66,840		-			1,554,777
	General and administrative			-			-		-		6,458,027			6,458,027
	Loss from investment in affiliate			-			-		-		21,543			21,543
	Operating expenses			694,523			793,414		66,840		6,479,570			8,034,347
	Operating income (loss)		$	984,411		$	1,133,512	$	234,020	$	(6,479,570	)	$	(4,127,627	)
			Core Standards					Scientific and
			and Contract					Regulatory
	Nine months ended September 28, 2013		Services segment			Ingredients		Consulting segment		Other			Total
						segment
	Net sales		$	4,978,727		$	2,032,616	$	808,610	$	(60,285	)	$	7,759,668
	Cost of sales			3,661,772			1,260,697		452,479		955			5,375,903
	Gross profit (loss)			1,316,955			771,919		356,131		(61,240	)		2,383,765
	Operating expenses:
	Sales and marketing			1,120,897			599,395		14,600		131,159			1,866,051
	General and administrative			-			-		-		4,155,792			4,155,792
	Loss from investment in affiliate			-			-		-		33,281			33,281
	Operating expenses			1,120,897			599,395		14,600		4,320,232			6,055,124
	Operating income (loss)		$	196,058		$	172,524	$	341,531	$	(4,381,472	)	$	(3,671,359	)
			Core Standards and					Scientific and
			Contract Services			Ingredients		Regulatory
								Consulting
	At September 27, 2014		segment			segment		segment		Other			Total
	Total assets		$	3,394,033		$	2,618,062	$	277,007	$	2,410,049		$	8,699,151
			Core Standards and					Scientific and
			Contract Services			Ingredients		Regulatory
Consulting
At December 28, 2013		segment			segment		segment		Other			Total
Total assets		$	2,952,270		$	1,083,856	$	139,765	$	4,811,001		$	8,986,892

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 27, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Note 10. Commitments and Contingencies	'
	Capitalized Lease Obligations
	During the nine months ended September 27, 2014, the Company entered into two financing transactions to purchase laboratory equipment.  Under the lease terms, the Company will make monthly future lease payments, including interest, of approximately $2,000 and $5,000, respectively, for 60 months, for a total payment of approximately $122,000 and $271,000, respectively.  The Company has recorded a capital lease of approximately $100,000 and $223,000, respectively.  The equipment will be utilized in our core standards and contract services segment.
	Employment Agreement with Troy Rhonemus
	On March 6, 2014, the Company entered into an Employment Agreement (the “Rhonemus Agreement”) with Mr. Troy Rhonemus pursuant to which Mr. Rhonemus was appointed to serve as the Chief Operating Officer of the Company.  The Rhonemus Agreement provides for a base salary of $180,000, and provides for an annual cash bonus (based on performance targets) of up to 30% of his base salary (30% of this salary being the “Maximum Annual Bonus”), and provides for option grants of 250,000 shares of Common Stock.  The option grants were awarded on February 21, 2014 at an exercise price of $1.75 per share, which vest 33% one year from the date of grant with the remainder vesting in 24 equal monthly installments thereafter.  Upon termination, Mr. Rhonemus will be entitled to any accrued but unpaid base salary and any accrued but unpaid welfare and retirement benefits up to the termination date.  In addition, if Mr. Rhonemus leaves the Company for “Good Reason” (as defined in the Rhonemus Agreement), he will also be entitled to severance equal to two weeks of base salary for each full year of service to a maximum of eight weeks of the base salary.   In the event the Company terminates Mr. Rhonemus’ employment “without Cause,” Mr. Rhonemus will be entitled to severance equal to two weeks of base salary for each full year of service to a maximum of eight weeks of the base salary, or, if Mr. Rhonemus enters into a standard separation agreement, Mr. Rhonemus will receive continuation of base salary and health benefits, together with applicable fringe benefits as provided until the expiration of the term or renewal term then in effect, however, that in the case of medical and dental insurance, until the expiration of 12 months from the date of termination.
	Legal Proceedings
	The Company from time to time is involved in legal proceedings in the ordinary course of our business, which can include employment claims, product claims and patent infringements.  We do not believe that any of these claims and proceedings against us as they arise are likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations.
	During the nine-month period ended September 27, 2014, the Company settled and paid approximately $125,000 to a certain claimant.  This payment was recognized in general and administrative expenses in the statements of operations for the nine-month period ended September 27, 2014.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 27, 2014
Subsequent Events [Abstract]	'
Note 11. Subsequent Events	'
	Subsequent to the nine-month period ended September 27, 2014, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Technology II, L.P., as lender (“Lender”) and Hercules Technology Growth Capital, Inc., as agent. Lender will provide us with access to a term loan of up to $5 million. The first $2.5 million of the term loan was funded at closing, and is repayable in equal monthly installments of principal and interest (mortgage style) over 30 months, following an initial interest-only period of twelve months after closing.  The remaining $2.5 million of the term loan can be drawn down at our option at any time but no later than July 31, 2015. In connection with the loan, the Company paid a $50,000 facility charge to Lender.
	The term loan bears interest at the rate per year equal to the greater of either (i) 9.35% plus the prime rate as reported in The Wall Street Journal minus 3.25%, and (ii) 9.35%. The Company may prepay all, but no less than all, of the outstanding loan balance, subject to prepayment charges of 3% during the first twelve months following closing, 2% during the next twelve months and 1% thereafter. On the earliest to occur of the (a) the loan maturity date, (b) the date the Company prepays the outstanding loan balance or (c) the date the outstanding loan balance becomes due and payable, the Company will pay Lender an end of term charge equal to 3.75% of all amounts drawn under the loan.
	The Loan Agreement further provides that, subject to certain conditions, any regularly scheduled installment of principal due to Lender may be paid, in whole or in part at the option of the Company or Lender, by converting a portion of the principal of the term loan into shares of the Company’s common stock (the “Conversion Shares”) at a conversion price of $1.293, in lieu of payment in cash.  The aggregate principal amount to be paid in Conversion Shares shall not exceed $1,000,000.  Of this amount 50% shall convert at the Lender’s option and 50% shall convert at the Company’s option.
	Pursuant to the Loan Agreement, the Company issued Lender a warrant (the “Warrant”) to purchase 419,020 shares of our common stock at an exercise price of $1.062 per share, subject to customary adjustments under certain circumstances.   The Warrant is exercisable beginning on the date of issuance and expires five years from that date.
	In connection with the Loan Agreement, the Company granted first priority liens and security interest in substantially all of our assets, exclusive of intellectual property and 35% of the capital stock of any foreign subsidiary, as collateral for the obligations under the Loan Agreement.  The Loan Agreement also contains representations and warranties by the Company and Lender, indemnification provisions in favor of Lender and customary covenants, and events of default.  Upon the occurrence of an event of default, a default interest rate of an additional 4% will be applied to the outstanding loan balances, and Lender may terminate its lending commitment, declare all outstanding obligations immediately due and payable, and take such other actions as set forth in the Loan Agreement.

Significant_Accounting_Policie1

Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 27, 2014
Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of presentation:  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company's fiscal year ends on the Saturday closest to December 31, and the Company’s normal fiscal quarters end on the Saturday 13 weeks after the last fiscal year end or fiscal quarter end.  Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date.  The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks, and will end on January 3, 2015.
Changes in accounting estimate	'
	Changes in accounting estimate: During the nine-month period ended September 27, 2014, the Company evaluated assumptions for estimating the fair value of the Company’s stock options.  The Company uses the Black-Scholes based option valuation model, which requires assumptions on (i) volatility, (ii) expected dividends, (iii) expected term and (iv) risk-free rate.  While evaluating the assumptions on volatility, the Company determined that the historical volatility the Company’s common stock needs to be considered when estimating the expected volatility.  Previously, the Company calculated expected volatility based on publicly held companies in similar industries and did not consider the historical volatility of the Company’s common stock, as the historical measurement period that was available to compute the volatility rate of the Company’s common stock was shorter than the expected life of the options.
	For the stock options granted during the nine-month period ended September 27, 2014, the Company calculated expected volatility rate based on the combined volatility of publicly held companies in similar industries and volatility of the Company’s common stock.  A 20~30% weight was assigned to the volatility of the Company’s common stock as the historical volatility of the Company’s common stock covers only the period since June 2008 in a thinly traded market.  The weighted average expected volatility for the stock options granted during the nine-month period ended September 27, 2014 following the update to our estimate is approximately 73%.  The weighted average expected volatility would have been approximately 30%, had we computed solely based on the volatility rates of similarly situated public companies. For the year ended December 28, 2013, the weighted average expected volatility the Company used to estimate the fair value of the Company’s stock options granted was approximately 33%.
Inventories	'
	Inventories:  Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  The amounts of major classes of inventory as of September 27, 2014 and December 28, 2013 are as follows:
		27-Sep-14		28-Dec-13
	Reference standards	$	1,715,507	$	1,769,160
	Bulk ingredients		866,509		694,965
			2,582,016		2,464,125
	Less valuation allowance		295,930		260,000
		$	2,286,086	$	2,204,125
Recent accounting standards	'
	Recent accounting standards: In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements.
	In August 2014, the FASB issued ASU 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.”  Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this ASU provide that guidance.  In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures.  The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued).  The amendments in this ASU are effective for public and nonpublic entities for annual periods ending after December 15, 2016. Early adoption is permitted. On September 27, 2014, the Company early adopted ASU 2014-15.  The adoption of ASU 2014-15 had no impacts on the Company’s consolidated financial statements.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 27, 2014
Accounting Policies [Abstract]	'
Inventories	'
		27-Sep-14		28-Dec-13
	Reference standards	$	1,715,507	$	1,769,160
	Bulk ingredients		866,509		694,965
			2,582,016		2,464,125
	Less valuation allowance		295,930		260,000
		$	2,286,086	$	2,204,125

Loss_Per_Share_Applicable_to_C1

Loss Per Share Applicable to Common Stockholders (Tables)	9 Months Ended
	Sep. 27, 2014
Loss Per Share Applicable To Common Stockholders Tables	'
Loss per share amounts applicable to common stockholders	'
		Three Months Ended						Nine Months Ended
		27-Sep-14			28-Sep-13			27-Sep-14			28-Sep-13
	Net loss	$	(659,653	)	$	(1,250,263	)	$	(4,160,811	)	$	(3,695,201	)
	Basic and diluted loss per common share	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.04	)
	Weighted average common shares outstanding (1):		106,610,400			101,309,939			106,290,782			98,590,008
	Potentially dilutive securities (2):
	Stock options		13,890,766			13,609,700			13,890,766			13,609,700
	Warrants		-			535,000			-			535,000
	(1) Includes 1,676,175 and 500,000 weighted average nonvested shares of restricted stock for the three months ended September 27, 2014 and September 28, 2013, respectively, and 1,606,380 and 500,000 weighted average nonvested shares of restricted stock for the nine months ended September 27, 2014 and September 28, 2013, respectively, which are participating securities that feature voting and dividend rights.
	(2) Excluded from the computation of loss per share as their impact is antidilutive.

Investment_in_Affiliate_Tables

Investment in Affiliate (Tables)	9 Months Ended
	Sep. 27, 2014
Investment In Affiliate Tables	'
Carrying value determination	'
		December 31,
		2013
	Sales	$	60,575
	Gross profit		33,619
	Net loss	$	(435,208	)
Change in Carrying Value and Ownership	'
	Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation
		Carrying			Ownership
		Value			Percentage
	At December 28, 2013	$	1,887,844			4.9	%
	Company's share of NeutriSci's loss for the three-month period ended December 31, 2013; previously not recognized due to a three-month lag		(21,543	)		-
	Proceeds from assignment of the Senior Note		(1,092,500	)		-
	At December 30, 2013	$	773,801			4.9	%

Leasehold_Improvements_and_Equ1

Leasehold Improvements and Equipment (Tables)	9 Months Ended
	Sep. 27, 2014
Leasehold Improvements And Equipment	'
Leasehold improvements and equipment	'
		27-Sep-14		28-Dec-13
	Laboratory equipment	$	3,028,644	$	2,782,364
	Leasehold improvements		495,240		491,125
	Computer equipment		329,737		372,851
	Furniture and fixtures		13,039		18,313
	Office equipment		7,877		7,877
	Construction in progress		159,277		40,126
			4,033,814		3,712,656
	Less accumulated depreciation		2,740,112		2,649,417
		$	1,293,702	$	1,063,239

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 27, 2014
Share-Based Compensation Tables	'
Weighted average assumptions of stock options granted	'
	Nine Months Ended September 27, 2014
	Expected volatility		73.55	%
	Expected dividends		0	%
	Expected term	5.7 years
	Risk-free rate		1.86	%
Service Period Based Stock Options	'
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 28, 2013		12,113,655		$	1.06		7.43
	Options Granted		2,033,987			1.37		10
	Options Classification from Employee to Non-Employee		(113,151	)		0.76
	Options Exercised		(511,642	)		0.88
	Options Expired		(253,900	)		1
	Options Forfeited		(628,634	)		1.11
	Outstanding at September 27, 2014		12,640,315		$	1.12		7.22	$	1,475,920
	Exercisable at September 27, 2014		8,822,108		$	1.13		6.53	$	1,071,805
Restricted stock awards granted to employees	'
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 28, 2013		500,000		$	0.69
	Granted		1,090,000			1.41
	Vested		-			-
	Forfeited		-			-
	Unvested shares at September 27, 2014		1,590,000		$	1.18
	Expected to Vest as of September 27, 2014		1,590,000		$	1.18
Non-Employee stock options	'
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 28, 2013		847,300		$	1.44		5.74
	Options Granted		90,000			1.24		10
	Options Classification from Employee to Non-Employee		113,151			0.76
	Options Exercised		-			-
	Options Forfeited		-			-
	Outstanding at September 27, 2014		1,050,451		$	1.35		5.73	$	64,067
	Exercisable at September 27, 2014		960,451		$	1.36		5.34	$	64,067
Restricted stock awards granted to non-employees	'
					Weighted Average
		Shares			Fair Value
	Unvested shares at December 28, 2013		-		$	-
	Granted		96,000			1.3
	Vested		(12,000	)		1.28
	Forfeited		-			-
	Unvested shares expected to vest at September 27, 2014		84,000		$	1.06

Business_Segments_Tables

Business Segments (Tables)	3 Months Ended																																						9 Months Ended
	Sep. 27, 2014													Dec. 31, 2013											Sep. 28, 2013														Sep. 27, 2014													Sep. 28, 2013
Business Segments Tables	'													'											'														'													'
Business Segmentation	'													'											'														'													'
		Core Standards				Scientific and																				Core Standards					Scientific and									Core Standards													Core Standards				Scientific and
		and Contract				Regulatory																				and Contract					Regulatory									and Contract				Regulatory									and Contract				Regulatory
	Three months ended September 27, 2014	Services		Ingredients		Consulting segment		Other			Total														Three months ended September 28, 2013	Services			Ingredients		Consulting segment		Other			Total			Nine months ended September 27, 2014	Services segment		Ingredients		Consulting segment		Other			Total			Nine months ended September 28, 2013	Services segment		Ingredients		Consulting segment		Other			Total
		segment		segment																						segment			segment													segment													segment
	Net sales	$	1,814,622	$	2,031,250	$	293,838	$	-		$	4,139,710													Net sales	$	1,574,970		$	780,489	$	362,749	$	-		$	2,718,207		Net sales	$	5,407,455	$	4,889,431	$	773,116	$	-		$	11,070,002		Net sales	$	4,978,727	$	2,032,616	$	808,610	$	(60,285	)	$	7,759,668
	Cost of sales		1,239,356		1,200,790		176,618		-			2,616,764													Cost of sales		1,309,562			484,511		173,947		-			1,968,020		Cost of sales		3,728,521		2,962,505		472,256		-			7,163,282		Cost of sales		3,661,772		1,260,697		452,479		955			5,375,903
	Gross profit		575,266		830,460		117,220		-			1,522,946													Gross profit		265,408			295,977		188,802		-			750,187		Gross profit		1,678,934		1,926,926		300,860		-			3,906,720		Gross profit (loss)		1,316,955		771,919		356,131		(61,240	)		2,383,765
	Operating expenses:																								Operating expenses:														Operating expenses:													Operating expenses:
	Sales and marketing		259,951		243,068		15,643		-			518,662													Sales and marketing		328,043			165,025		12,000		-			505,068		Sales and marketing		694,523		793,414		66,840		-			1,554,777		Sales and marketing		1,120,897		599,395		14,600		131,159			1,866,051
	General and administrative		-		-		-		1,651,718			1,651,718													General and administrative		-			-		-		1,453,611			1,453,611		General and administrative		-		-		-		6,458,027			6,458,027		General and administrative		-		-		-		4,155,792			4,155,792
	Operating expenses		259,951		243,068		15,643		1,651,718			2,170,380													Loss from investment in affiliate		-			-		-		33,281			33,281		Loss from investment in affiliate		-		-		-		21,543			21,543		Loss from investment in affiliate		-		-		-		33,281			33,281
																									Operating expenses		328,043			165,025		12,000		1,486,892			1,991,960		Operating expenses		694,523		793,414		66,840		6,479,570			8,034,347		Operating expenses		1,120,897		599,395		14,600		4,320,232			6,055,124
	Operating income (loss)	$	315,315	$	587,392	$	101,577	$	(1,651,718	)	$	(647,434	)
																									Operating income (loss)	$	(62,635	)	$	130,952	$	176,802	$	(1,486,892	)	$	(1,241,773	)	Operating income (loss)	$	984,411	$	1,133,512	$	234,020	$	(6,479,570	)	$	(4,127,627	)	Operating income (loss)	$	196,058	$	172,524	$	341,531	$	(4,381,472	)	$	(3,671,359	)
Total assets	'													'											'														'													'
		Core Standards and				Scientific and									Core Standards and				Scientific and
		Contract Services		Ingredients		Regulatory									Contract Services		Ingredients		Regulatory
						Consulting													Consulting
	At September 27, 2014	segment		segment		segment		Other			Total			At December 28, 2013	segment		segment		segment		Other		Total
	Total assets	$	3,394,033	$	2,618,062	$	277,007	$	2,410,049		$	8,699,151		Total assets	$	2,952,270	$	1,083,856	$	139,765	$	4,811,001	$	8,986,892

Nature_of_Business_and_Liquidi1

Nature of Business and Liquidity (Details Narrative) (USD $)	1 Months Ended	3 Months Ended				9 Months Ended
	Nov. 05, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013	Dec. 28, 2013
Liquidity	'	'	'	'	'	'	'	'
Operating (loss)	'	($647,434)	'	'	($1,241,773)	($4,127,627)	($3,671,359)	'
Net (loss)	'	-659,653	-1,653,142	-1,848,016	-1,250,263	-4,160,811	-3,695,201	'
Cash and cash equivalents	'	1,203,758	'	'	1,087,424	1,203,758	1,087,424	2,261,336
Term loan maximum amount	5,000,000	'	'	'	'	'	'	'
Term loan amount funded at closing	2,500,000	'	'	'	'	'	'	'
Term of loan, following an interest only period	'30 months	'	'	'	'	'	'	'
Interest only period	'12 months	'	'	'	'	'	'	'
Term loan, unfunded amount available for future draw	$2,500,000	'	'	'	'	'	'	'

Significant_Accounting_Policie3

Significant Accounting Policies (Details) (USD $)	Sep. 27, 2014	Dec. 28, 2013
Inventories	'	'
Reference standards	$1,715,507	$1,769,160
Bulk ingredients	866,509	694,965
Inventory-gross	2,582,016	2,464,125
Less valuation allowance	295,930	260,000
Inventory-net	$2,286,086	$2,204,125

Significant_Accounting_Policie4

Significant Accounting Policies (Details Narrative)	9 Months Ended	12 Months Ended
	Sep. 27, 2014	Dec. 28, 2013
Significant Accounting Policies Details Narrative	'	'
Volatility weight, minimum	20.00%	'
Volatility weight, maximum	30.00%	'
Weighted average expected volatility	73.00%	33.00%

Loss_Per_Share_Applicable_to_C2

Loss Per Share Applicable to Common Stockholders (Details) (USD $)	3 Months Ended						9 Months Ended
	Sep. 27, 2014		Jun. 28, 2014	Mar. 29, 2014	Sep. 28, 2013		Sep. 27, 2014		Sep. 28, 2013
Net loss	($659,653)		($1,653,142)	($1,848,016)	($1,250,263)		($4,160,811)		($3,695,201)
Earnings per share	'		'	'	'		'		'
Basic and diluted loss per common share	($0.01)		'	'	($0.01)		($0.04)		($0.04)
Weighted average common shares outstanding	106,610,400	[1]	'	'	101,309,939	[1]	106,290,782	[1]	98,590,008	[1]
Stock Options [Member]	'		'	'	'		'		'
Earnings per share	'		'	'	'		'		'
Potentially dilutive securities	13,890,766	[2]	'	'	13,609,700	[2]	13,890,766	[2]	13,609,700	[2]
Warrant [Member]	'		'	'	'		'		'
Earnings per share	'		'	'	'		'		'
Potentially dilutive securities	'	[2]	'	'	535,000	[2]	'	[2]	535,000	[2]
[1]	Includes 1,676,175 and 500,000 weighted average nonvested shares of restricted stock for the three months ended September 27, 2014 and September 28, 2013, respectively, and 1,606,380 and 500,000 weighted average nonvested shares of restricted stock for the nine months ended September 27, 2014 and September 28, 2013, respectively, which are participating securities that feature voting and dividend rights.
[2]	Excluded from the computation of loss per share as their impact is antidilutive.

Loss_Per_Share_Applicable_to_C3

Loss Per Share Applicable to Common Stockholders (Details Narrative)	3 Months Ended		9 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Loss Per Share Applicable To Common Stockholders Details Narrative	'	'	'	'
Weighted average nonvested shares of restricted stock	1,676,175	500,000	1,606,380	500,000

Investment_in_Affiliate_Detail

Investment in Affiliate (Details 1) (USD $)	3 Months Ended
	Dec. 31, 2013
Equity Method Investments and Joint Ventures [Abstract]	'
Sales	$60,575
Gross profit	33,619
Net loss	($435,208)

Investment_in_Affiliate_Detail1

Investment in Affiliate (Details 2) (NeutriSci [Member], USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 30, 2013	Dec. 28, 2013	Dec. 29, 2012
NeutriSci [Member]	'	'	'	'
Carrying value, equity investment	'	$773,801	$1,887,844	$2,157,804
Company's share of NeutriSci's loss for the three-month period ended December 31, 2013;	-21,543	'	'	'
Proceeds from assignment of the Senior Note	($1,092,500)	'	'	'
Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation	'	'	'	'
Ownership percentage	'	4.90%	4.90%	'

Investment_in_Affiliate_Detail2

Investment in Affiliate (Details Narrative) (USD $)	9 Months Ended					12 Months Ended
	Sep. 27, 2014	Sep. 27, 2014	Sep. 27, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 28, 2013	Dec. 30, 2013	Dec. 28, 2013
		Exchange Listing [Member]	Exchange Listing [Member]	Not Listed [Member]	Not Listed [Member]	NeutriSci [Member]	NeutriSci [Member]	NeutriSci [Member]
		Series I Unrelated Party [Member]	Series I Paladium [Member]	Series I Unrelated Party [Member]	Series I Paladium [Member]
Sale transaction value, cost recovery method	'	'	'	'	'	$3,157,804	'	'
Secured note	'	'	'	'	'	2,500,000	'	'
Convertible shares	'	'	'	'	'	625,000	'	'
Series I preferres shares issued	'	'	'	'	'	669,708	'	'
Series I conversion into Class A Common Shares	'	'	'	'	'	2,678,832	'	'
Class A common percent of deemed shares	'	'	'	'	'	19.00%	'	'
Series I shares due upon stock exchange listing contingency	'	110,000	11,000	250,000	25,000	'	'	'
Carrying value, equity investment, beginning balance	'	'	'	'	'	2,157,804	773,801	1,887,844
Cash payment received	'	'	'	'	'	1,000,000	'	'
Series I shares held by the Company	670,658	'	'	'	'	'	'	'
Senior note to an unrelated party	1,250,000	'	'	'	'	'	'	'
Remaining outstanding on the Senior Note at the date of assignment	2,275,000	'	'	'	'	'	'	'
Legal fees	7,500	'	'	'	'	'	'	'
NeutriSci Preferred shares due to an unrelated party	500,000	'	'	'	'	'	'	'
Placement agent cash fee	150,000	'	'	'	'	'	'	'
NeutriSci Preferred shares due to Palladium	50,000	'	'	'	'	'	'	'
Net proceeds of note assignment	$1,092,500	'	'	'	'	'	'	'

Leasehold_Improvements_and_Equ2

Leasehold Improvements and Equipment (Details) (USD $)	Sep. 27, 2014	Dec. 31, 2013
Leasehold improvements	'	'
Laboratory equipment	$3,028,644	$2,782,364
Leasehold improvements	495,240	491,125
Computer equipment	329,737	372,851
Furniture and fixtures	13,039	18,313
Office equipment	7,877	7,877
Construction in progress	159,277	40,126
Leasehold improvements, gross	4,033,814	3,712,656
Less accumulated depreciation	2,740,112	2,649,417
Leasehold improvements, total	$1,293,702	$1,063,239

Leasehold_Improvements_and_Equ3

Leasehold Improvements and Equipment (Details Narrative) (USD $)	9 Months Ended
	Sep. 27, 2014	Sep. 28, 2013
Leasehold Improvements And Equipment Details Narrative	'	'
Depreciation expense on leasehold improvements and equipment	$161,712	$187,667
Disposed fully depreciated equipment	$56,000	'

ShareBased_Compensation_Assump

Share-Based Compensation - Assumptions (Details)	9 Months Ended
	Sep. 27, 2014
Share-Based Compensation - Assumptions Details	'
Expected volatility	73.55%
Expected dividends	0.00%
Expected term	'5 years 8 months 12 days
Risk-free rate	1.86%

ShareBased_Compensation_Servic

Share-Based Compensation - Service Based (Details 1) (USD $)	9 Months Ended
	Sep. 27, 2014
Number of Shares	'
Outstanding at Beginning of Period	12,113,655
Options Granted	2,033,987
Options Classification from Employee to Non-Employee	($113,151)
Options Exercised	-511,642
Options Expired	-253,900
Options Forfeited	-628,634
Outstanding at End of Period	12,640,315
Exercisable at End of Period	8,822,108
Weighted Average Exercise Price	'
Outstanding at Beginning of Period	$1.06
Options Granted	$1.37
Options Classification from Employee to Non-Employee	$0.76
Options Exercised	$0.88
Options Expired	$1
Options Forfeited	$1.11
Outstanding at End of Period	$1.12
Exercisable at End of Period	$1.13
Weighted Average Remaining Contractual Term	'
Outstanding at Beginning of Period	'7 years 5 months 5 days
Options Granted	'10 years 0 months 0 days
Outstanding at End of Period	'7 years 2 months 19 days
Exercisable at End of Period	'6 years 6 months 10 days
Aggregate Intrinsic Value	'
Outstanding at End of Period	1,475,920
Exercisable at End of Period	$1,071,805

ShareBased_Compensation_Employ

Share-Based Compensation - Employees - Restricted Stock (Details 2) (Employee Restricted Stock [Member], USD $)	9 Months Ended
	Sep. 27, 2014
Employee Restricted Stock [Member]	'
Summary of activity of restricted stock awards granted to employees- Shares	'
Unvested shares at Beginning of Period	500,000
Granted	1,090,000
Vested	'
Forfeited	'
Unvested shares at End of Period	1,590,000
Expected to Vest as of End of Period	1,590,000
Weighted Average Award-Date Fair Value	'
Unvested shares at Beginning of Period	$0.69
Granted	$1.41
Vested	'
Forfeited	'
Unvested shares at End of Period	$1.18
Expected to Vest as of End of Period	$1.18

ShareBased_Compensation_NonEmp

Share-Based Compensation - NonEmployee (Details 3) (USD $)	9 Months Ended
	Sep. 27, 2014
Non-Employee Share-Based Compensation- Options	'
Outstanding at Beginning of Period	847,300
Options Granted	90,000
Options Classification from Employee to Non-Employee	113,151
Options Exercised	'
Options Forfeited	'
Outstanding at End of Period	1,050,451
Exercisable at End of Period	960,451
Weighted Average Exercise Price	'
Outstanding at Beginning of Period	$1.44
Options Granted	$1.24
Options Classification from Employee to Non-Employee	$0.76
Options Exercised	'
Options Forfeited	'
Outstanding at End of Period	$1.35
Exercisable at End of Period	$1.36
Weighted Average Remaining Contractual Term	'
Outstanding at Beginning of Period	'5 years 8 months 26 days
Options Granted	'10 years
Outstanding at End of Period	'5 years 8 months 25 days
Exercisable at End of Period	'5 years 8 months 25 days
Aggregate Intrinsic Value	'
Outstanding at End of Period	$64,067
Exercisable at End of Period	$64,067

ShareBased_Compensation_Restri

Share-Based Compensation - Restricted Stock (Details 4) (NonEmployee Restricted Stock [Member], USD $)	9 Months Ended
	Sep. 27, 2014
NonEmployee Restricted Stock [Member]	'
Unvested shares at Beginning of Period	'
Granted	96,000
Vested	-12,000
Forfeited	'
Unvested shares expected to vest at End of Period	84,000
Weighted Average Award-Date Fair Value	'
Unvested shares at Beginning of Period	'
Granted	$1.30
Vested	$1.28
Forfeited	'
Unvested shares at End of Period	$1.06

ShareBased_Compensation_Detail

Share-Based Compensation (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Options issued	'	'	90,000	'
Employee Comp [Member]	'	'	'	'
Weighted average fair value of options granted	'	'	$0.91	'
Closing stock price	$1.06	'	$1.06	'
Unrecognized stock option expense	$2,035,000	'	$2,035,000	'
Cost is expected to be recognized over a weighted average period	'P2Y1M13D	'	'	'
Restricted stock award to officers and board	'	'	1,090,000	'
General and administrative expenses	388,000	244,000	2,359,000	817,000
NonEmployee Compensation [Member]	'	'	'	'
General and administrative expenses	43,000	87,000	'	'
Common stock shares awarded, shares	65,000	'	'	'
Common stock shares awarded, fair value	83,850	'	'	'
Common stock shares awarded, period of expense to be recognized	'7 months	'	'	'
Common stock shares awarded, expense of award	35,000	'	'	'
Stock award, period of expense expected to be recognized over	'4 months	'	'	'
Restricted stock, period of expense expected to be recognized over	'3 years 4 months 25 days	'	'	'
NonEmployee Comp [Member]	'	'	'	'
General and administrative expenses	'	'	109,000	243,000
Common stock shares awarded, shares	'	'	600,000	'
Common stock shares awarded, expense of award	'	'	238,000	'
Unrecognized expense related to stock awards	49,000	'	49,000	'
Unrecognized expense related to restricted stock awards	87,000	'	87,000	'
Fair value of vested restricted stock awards	'	'	$15,000	'

Stock_Issuance_Details_Narrati

Stock Issuance (Details Narrative) (USD $)	Jun. 18, 2014	Jun. 11, 2014
Stock Issuance Details Narrative	'	'
Shares of common stock issued to vendor	82,000	44,605
Payment to vendor for outstanding balance	$76,306	$52,188
Monthly retainer fee payments	$3,000	'

Business_Segments_Details

Business Segments (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Net sales	$4,139,710	$2,718,207	$11,070,002	$7,759,668
Cost of sales	2,616,764	1,968,020	7,163,282	5,375,903
Gross profit (loss)	1,522,946	750,187	3,906,720	2,383,765
Sales and marketing	518,662	505,068	1,554,777	1,866,051
General and administrative	1,651,718	1,453,611	6,458,027	4,155,792
Loss from investment in affiliate	'	33,281	21,543	33,281
Operating expenses	2,170,380	1,991,960	8,034,347	6,055,124
Operating income (loss)	-647,434	-1,241,773	-4,127,627	-3,671,359
CoreStandardsContractServices [Member]	'	'	'	'
Net sales	1,814,622	1,574,970	5,407,455	4,978,727
Cost of sales	1,239,356	1,309,562	3,728,521	3,661,772
Gross profit (loss)	575,266	265,408	1,678,934	1,316,955
Sales and marketing	259,951	328,043	694,523	1,120,897
General and administrative	'	'	'	'
Loss from investment in affiliate	'	'	'	'
Operating expenses	259,951	328,043	694,523	1,120,897
Operating income (loss)	315,315	-62,635	984,411	196,058
Ingredients Segment [Member]	'	'	'	'
Net sales	2,031,250	780,489	4,889,431	2,032,616
Cost of sales	1,200,790	484,511	2,962,505	1,260,697
Gross profit (loss)	830,460	295,977	1,926,926	771,919
Sales and marketing	243,068	165,025	793,414	599,395
General and administrative	'	'	'	'
Loss from investment in affiliate	'	'	'	'
Operating expenses	243,068	165,025	793,414	599,395
Operating income (loss)	587,392	130,952	1,133,512	172,524
Scientific Regulatory [Member]	'	'	'	'
Net sales	293,838	362,749	'	'
Cost of sales	176,618	173,947	'	'
Gross profit (loss)	117,220	188,802	'	'
Sales and marketing	15,643	12,000	'	'
General and administrative	'	'	'	'
Loss from investment in affiliate	'	'	'	'
Operating expenses	15,643	12,000	'	'
Operating income (loss)	101,577	176,802	'	'
Other Segment [Member]	'	'	'	'
Net sales	'	'	'	-60,285
Cost of sales	'	'	'	955
Gross profit (loss)	'	'	'	-61,240
Sales and marketing	'	'	'	131,159
General and administrative	1,651,718	1,453,611	6,458,027	4,155,792
Loss from investment in affiliate	'	33,281	21,543	33,281
Operating expenses	1,651,718	1,486,892	6,479,570	4,320,232
Operating income (loss)	-1,651,718	-1,486,892	-6,479,570	-4,381,472
Scientific Regulatory [Member]	'	'	'	'
Net sales	'	'	773,116	808,610
Cost of sales	'	'	472,256	452,479
Gross profit (loss)	'	'	300,860	356,131
Sales and marketing	'	'	66,840	14,600
General and administrative	'	'	'	'
Loss from investment in affiliate	'	'	'	'
Operating expenses	'	'	66,840	14,600
Operating income (loss)	'	'	$234,020	$341,531

Business_Segments_Details_1

Business Segments (Details 1) (USD $)	Sep. 27, 2014	Dec. 28, 2013
Total assets	$8,699,151	$8,986,892
CoreStandardsContractServices [Member]	'	'
Total assets	3,394,033	2,952,270
Ingredients Segment [Member]	'	'
Total assets	2,618,062	1,083,856
ScientificRegulatory [Member]	'	'
Total assets	277,007	139,765
Other Segment [Member]	'	'
Total assets	$2,410,049	$4,811,001

Commitments_and_Contingencies_

Commitments and Contingencies (Details Narrative) (USD $)	9 Months Ended
	Sep. 27, 2014
Capital lease term	'60 months
Settlement amount	$125,000
Lease 1 [Member]	'
Monthly lease payment	2,000
Capital lease future payments	122,000
Capital lease	100,000
Lease 2 [Member]	'
Monthly lease payment	5,000
Capital lease future payments	271,000
Capital lease	223,000
Chief Operating Officer [Member]	'
Base salary	$180,000
Maximum annual cash bonus percentage	30.00%
Option grants	250,000

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	1 Months Ended
	Nov. 05, 2014	Sep. 27, 2014	Sep. 27, 2014	Sep. 27, 2014
		Prepayment Fee 12 Month [Member]	Prepayment Fee 13-24 Month [Member]	Prepayment Fee Thereafter [Member]
Term loan maximum amount	$5,000,000	'	'	'
Term loan amount funded at closing	2,500,000	'	'	'
Term of loan	'30 months	'	'	'
Interest only period	'12 months	'	'	'
Term loan, unfunded amount available for future draw	2,500,000	'	'	'
Facility charge	50,000	'	'	'
Term loan interest rate	9.35%	'	'	'
Prepayment charge	'	3.00%	2.00%	1.00%
End of term charge	3.75%	'	'	'
Conversion price	$1.29	'	'	'
Principal paid in Conversion Shares, maximum value	$1,000,000	'	'	'
Warrant issued	419,020	'	'	'
Warrant exercise price	$1.06	'	'	'
Priority lien and security interest excluding foreign subsidiary capital stock	35.00%	'	'	'
Default interest rate	4.00%	'	'	'